ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "proteomics"

  • Abstract Number: 2362 • ACR Convergence 2023

    Identification of Protein Biomarkers Associated with the Severity and Risk of Progression of Interstitial Lung Disease in VEDOSS and Established Systemic Sclerosis Patients

    Thierry Sornasse1, Vishal Kakkar2, Rebecca Ross3, Sunhwa Kim4 and Francesco Del Galdo5, 1AbbVie, Inc., North Chicago, IL, 2University of Leeds, Leeds, United Kingdom, 3Medicine and Health, University of Leeds, Leeds, United Kingdom, 4AbbVie, Inc., South San Francisco, CA, 5University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom

    Background/Purpose: Pulmonary Fibrosis (PF) is one of the primary causes of systemic sclerosis (SSc)-related death. Hence, monitoring and predicting the course of PF in SSc…
  • Abstract Number: 0938 • ACR Convergence 2023

    Deconvolution of the Molecular Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: A Biomarker Blueprint of Scleroderma Disease Continuum

    Sunhwa Kim1, Thierry Sornasse2, Vishal Kakkar3, Rebecca Ross4, Yingtao Bi5, Hengcheng Hu2, Lisa Hazelwood2, Lauren Reinke-Breen6, jozsef karman7, Chris Butler2, Jennifer Van Camp2 and Francesco Del Galdo8, 1AbbVie, Inc., South San Francisco, CA, 2AbbVie, Inc., North Chicago, IL, 3University of Leeds, Leeds, United Kingdom, 4Medicine and Health, University of Leeds, Leeds, United Kingdom, 5AbbVie, Inc., Worcester, MA, 6AbbVie, Inc., Vernon Hills, IL, 7AbbVie, Inc., San Francisco, CA, 8University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease that affects multiple organs asynchronously, leading to highly variable fibrotic damage and consequent increased morbidity and mortality.…
  • Abstract Number: 2427 • ACR Convergence 2023

    Degranulating PR3+ Myeloid Cells Characterize Proliferative Lupus Nephritis

    Alessandra Ida Celia1, Xiaoping Yang2, Hana Minsky2, Silvia Malvica2, Michelle Petri3, the Accelerating Medicines Partnership in RA/SLE4, Avi Rosenberg5 and Andrea Fava2, 1John Hopkins University of Medicine, Rome, Italy, 2Johns Hopkins University, Baltimore, MD, 3Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 4Multiple, Multiple, 5Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: As part of the Accelerating Medicines Partnership (AMP), we discovered that urinary PR3, a neutrophil degranulation product, is associated with histological activity, indicating the…
  • Abstract Number: 0939 • ACR Convergence 2023

    HRCT-derived Delta Radiomic Features Classify Response to Anti-Fibrotic Treatment in Experimental and Human Fibrosing Interstitial Lung Disease

    David Lauer1, Luca Romano Kolly1, Hubert Gabrys2, Matthias Brunner1, Malgorzata Anna Maciukiewicz1, Thomas Frauenfelder3, Stephanie Tanadini-Lang2, Anne-Christine Uldry4, Manfred Heller4, Kerstin Klein5, Oliver Distler6, Janine Gote-Schniering1 and Britta Maurer7, 1University Hospital Bern, Bern, Switzerland, 2University Hospital Zurich, Zurich, Switzerland, 3Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 4University of Bern, Bern, Switzerland, 5Department of Rheumatology and Immunology, University Hospital Bern, Bern, Switzerland, 6Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 7University Hospital Bern, University Bern, Bern, Switzerland

    Background/Purpose: Quantification of response to anti-fibrotic drugs in patients with fibrosing interstitial lung disease (ILD) relies on repeated pulmonary function tests (PFT) and visual evaluation…
  • Abstract Number: 2495 • ACR Convergence 2023

    Unbiased Proteomic Approach to Identify Novel Biomarkers of Disease Activity in ANCA- Associated Vasculitis

    Natalie Atallah1, Vahe Panossian2, Xiaoqing Fu1, Claire Cook1 and Zachary Wallace3, 1Massachusetts General Hospital, Boston, MA, 2American University of Beirut, Beirut, Lebanon, 3Massachusetts General Hospital, Newton, MA

    Background/Purpose: Identifying novel biomarkers of disease activity could improve outcomes by facilitating personalized approaches to treatment decisions in ANCA-associated vasculitis. Biomarkers of disease activity used…
  • Abstract Number: 0946 • ACR Convergence 2023

    Immunoglobulins G Purified from Systemic Sclerosis Patients Influence Cytoplasmic and Nuclear Proteins Profile in Dermal Fibroblasts

    Aurélien Chepy1, Marie Duhamel2, Solange Vivier1, Clément Chauvet1, Lucile Guilbert3, Eric Hachulla4, Sylvain Dubucquoi1, David Launay1, Michel Salzet2 and Vincent Sobanski1, 1Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France, 2Univ. Lille, Inserm, CHU Lille, U1192 - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, Lille, France, 3CHU Lille, Institut d’Immunologie, Lille, France, 4CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France

    Background/Purpose: Autoantibodies (Aab) are frequent in systemic sclerosis (SSc). While recognized as potent biomarkers, their pathogenic role is unclear. Recently, we showed that immunoglobulins G…
  • Abstract Number: 2581 • ACR Convergence 2023

    Proteomic Signatures in Pre-Rheumatoid Arthritis Suggest Evolving Biological Pathways in Different Stages of Disease Development That May Inform Prediction and Prevention Strategies

    Samir Rachid Zaim1, Adam Savage1, Mark Gillespie1, Christy Bennett1, lynne Becker1, LauraKay Moss2, Marie Feser2, Jess Edison3, Ted R Mikuls4, Michael Holer2, kevin Deane2 and Xiao-Jun Li1, 1Allen Institute for Immunology, Seattle, WA, 2University of Colorado Anschutz Medical Campus, Aurora, CO, 3Walter Reed Military Medical Center, Bethesda, MD, 4Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Rheumatoid arthritis (RA) includes a stage of development that can be termed 'pre-RA' and defined as the presence of abnormal biomarkers and/or other features…
  • Abstract Number: 0962 • ACR Convergence 2023

    Topological Proteomic Differences in Fibrotic and Unaffected Skin in Scleroderma

    Irene Choi1, Courtney Yu2, Francesco Boin1, Elizabeth Volkmann3, Stephanie Stanford2 and Nunzio Bottini4, 1Cedars-Sinai Medical Center, Los Angeles, CA, 2University of California San Diego, San Diego, CA, 3University of California Los Angeles, Los Angeles, CA, 4University of California, San Francisco, CA

    Background/Purpose: Scleroderma (SSc) is a chronic autoimmune and rheumatic disease characterized by varying levels of tissue fibrosis in the skin and other internal organs. It…
  • Abstract Number: 2601 • ACR Convergence 2023

    Identification of Giant Cell Arteritis Using Plasma Proteome Profiles Integrated with Machine Learning

    kevin cunningham1, Jaeyun Sung2, Benjamin Hur2, VINOD GUPTA2, Matthew Koster2, Cornelia M. Weyand3, David Cuthbertson4, Nader Khalidi5, Curry Koening6, Carol Langford7, Carol McAlear8, Paul Monach9, Larry Moreland10, Christian Pagnoux11, Rennie Rhee8, Philip Seo12, Peter Merkel8 and Kenneth Warrington2, 1University of Minnesota, Minneapolis, MN, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic School of Medicine and Stanford University, Rochester, MN, 4University of South Florida, Tampa, FL, 5McMaster University, Hamilton, ON, Canada, 6University of Texas Dell Medical School, Austin, TX, 7Cleveland Clinic, Cleveland, OH, 8University of Pennsylvania, Philadelphia, PA, 9VA Boston Healthcare System, Boston, MA, 10University of Colorado, Denver, CO, 11Mount Sinai Hospital, Toronto, ON, Canada, 12Johns Hopkins University, Baltimore, MD

    Background/Purpose: The availability of diagnostic laboratory tests and specific biomarkers of disease activity for giant cell arteritis (GCA) remains an area of unmet need. The…
  • Abstract Number: 1608 • ACR Convergence 2023

    Plasma Proteomic Profiling in Antiphospholipid Antibody-positive Patients with Different Clinical Phenotypes: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry

    Ayesha Butt1, Rolando Garcia Milian1, George Goshua1, Sean Gu1, Eugenia Chock2, Valentina Restrepo1, John Hwa1, Hyung Chun1, H Michael Belmont3, Kello Nina4, D. Ware Branch5, Michelle Petri6, Jason Knight7, Rohan Willis8, Maria Laura Bertolaccini9, Doruk Erkan10, Alfred lee1, Anish Sharda1 and Alexander Pine11, 1Yale School of Medicine, New Haven, CT, 2Yale School of Medicine, Greenwich, CT, 3NYU School of Medicine, New York, NY, 4Northwell Health, Brooklyn, NY, 5University of Utah, Salt Lake City, UT, 6Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 7University of Michigan, Ann Arbor, MI, 8University of Texas Medical Branch, Galveston, TX, 9King's College London, London, United Kingdom, 10Hospital for Special Surgery, New York, NY, 11VA Connecticut/Yale School of Medicine, West Haven, CT

    Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with thrombotic and obstetric complications arising via a model of immunothrombosis. Patients may present with a spectrum…
  • Abstract Number: 0536 • ACR Convergence 2022

    Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria

    Andrea Fava1, Laurence S Magder2, Daniel W. Goldman3, Jill Buyon4, Betty Diamond5, Joel Guthridge6, William Apruzzese7, Derek Fine1, Jose Monroy-Trujillo1, Mohamed G. Atta1, Peter Izmirly4, H Michael Belmont8, Anne Davidson5, Maria Dall'Era9, Deepak Rao7, Arnon Arazi10, Nir Hacohen11, Soumya Raychaudhuri7, the Accelerating Medicines Partnership (AMP) RA/SLE12 and Michelle Petri3, 1Johns Hopkins University, Baltimore, MD, 2University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, 3Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 4NYU Grossman School of Medicine, New York, NY, 5Feinstein Institutes for Medical Research, Manhasset, NY, 6Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Brigham and Women's Hospital, Boston, MA, 8NYU School of Medicine, New York, NY, 9University of California, San Francisco, San Francisco, 10Feinstein Institutes for Medical Research, Melrose, MA, 11Broad Institute, Cambridge, MA, 12Multiple Insitutions

    Background/Purpose: A decline of urine protein-to-creatinine ratio (UPCR) to < 0.5 is associated with better long-term preservation of kidney function in lupus nephritis (LN). UPCR…
  • Abstract Number: 1962 • ACR Convergence 2022

    Idiopathic Pulmonary Fibrosis Molecular Profile Correlates with Stage of Rheumatoid Arthritis-Associated Interstitial Lung Disease

    Daniel Kass1, Mehdi Nouraie1, Yingze Zhang1, Bryant England2, Ted Mikuls3, Gail Kerr4, Andreas Reimold5, Kevin Gibson1, Marilyn Glassberg6, Paul Dellaripa7, Tracy Doyle7, Chester Oddis8 and Dana Ascherman8, 1University of Pittsburgh School of Medicine, Pittsburgh, PA, 2University of Nebraska Medical Center, Omaha, NE, 3Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 4Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 5North Texas Veterans Administration Health Care System, Dallas, TX, 6Loyola University Chicago Stritch School of Medicine, Chicago, IL, 7Brigham and Women's Hospital, Boston, MA, 8University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Previous studies have demonstrated clinical, epidemiologic, histopathologic, and genetic overlap between advanced rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and Idiopathic Pulmonary Fibrosis (IPF). Corresponding…
  • Abstract Number: 0611 • ACR Convergence 2022

    Proteomics Reveals Dysregulated Molecular Mechanisms of Cell Death in Neutrophils in Rheumatoid Arthritis

    Jennifer Amsler1, Constance Beaudouin2, Morgane LeGall3, Géraldine Falgarone4, François Rannou5, Léa Tourneur3 and Véronique Witko-Sarsat3, 1Institute Cochin, Schoenenwerd, Switzerland, 2Hôpital Privé de Provence, Aix-en-Provence, France, 3Institute Cochin, Paris, France, 4Hôpital Avicenne, Paris, France, 5Hôpital Cochin, Paris, France

    Background/Purpose: Favoring apoptosis of neutrophils infiltrating the joints of patients suffering from rheumatoid arthritis (RA) and perpetuating inflammation has recently been discussed as an alternative…
  • Abstract Number: 2135 • ACR Convergence 2022

    Evaluation of Candidate Protein Biomarkers to Predict Treatment Response in Patients with Psoriatic Arthritis

    James C Waddington1, Ruoyi Zhou1, Orla Coleman1, Bruna Wundervald2, Andrew Parnell3, Vinod Chandran4, Lara Fallon5, Douglass Chapman6, Remy Pollock7, Shibing Deng8, Oliver FitzGerald9, Stephen R Pennington10 and Philip J Mease11, 1Atturos, Dublin, Ireland, 2Atturos/Hamilton Institute, Maynooth University, Dublin, Ireland, 3Hamilton Institute, Maynooth University, Kildare, Ireland, 4Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 5Pfizer Inc, Montréal, QC, Canada, 6Pfizer Inc, New York, NY, 7Pfizer Canada ULC, Kirkland QC, Canada, 8Pfizer Inc, Waterford, MI, 9Conway Institute, University College Dublin, Dublin, Ireland, 10Atturos/Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, 11Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA.1,2 Using two mass spectrometry (MS)-based proteomic approaches (targeted multiple reaction monitoring [MRM]…
  • Abstract Number: 0616 • ACR Convergence 2022

    Serum Proteomic Networks Associate with Pre-clinical Rheumatoid Arthritis Autoantibodies and Longitudinal Outcomes

    Liam O'Neil1, XIAOBO MENG1, Caitin McFadyen1, Marvin Fritzler2 and Hani El-Gabalawy1, 1University of Manitoba, Winnipeg, MB, Canada, 2University of Calgary, Calgary, AB, Canada

    Background/Purpose: The detection of anti-citrullinated protein antibodies (ACPA) is associated with increased risk for development of future Rheumatoid Arthritis (RA). The biological events that underpin…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology